Bionano Genomics, Inc. BNGO
Biotechnology: Laboratory Analytical Instruments · IPO 2018 · data as of November 13, 2026
Bionano Genomics, Inc. (BNGO) is a industrial company listed in the US with a market value of about $14M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$30M, a net margin of -96.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).
Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -99%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 56% above the current price.
About Bionano Genomics
Bionano Genomics is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2018. Revenue went from $10M in 2017 to $29M in 2025, growth of about 14.7% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 1030% over three years (dilution for shareholders). It spends 40% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | $29M | $31M | $36M | $28M | $18M | $9M | $10M | $12M | $10M |
| Net income | -$30M | -$26M | -$112M | -$232M | -$133M | -$72M | -$41M | -$30M | -$18M | -$23M |
| Free cash flow | — | — | — | — | — | — | -$38M | -$30M | -$20M | -$22M |
| EPS (diluted) | $-1.97 | $-4.85 | $-88.13 | $-408.60 | $-274.88 | $-156.05 | $-234.07 | $-1194.35 | $-1566.46 | $-5191.52 |
| Net margin | -96.9% | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% |
| ROIC | — | -55.3% | -213.3% | -166.9% | -40.5% | -20.8% | -56.9% | -86.3% | -84.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Bionano Genomics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 56% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bionano Genomics pay a dividend?
Not currently.
Is Bionano Genomics a good stock to buy?
We do not give buy or sell advice. Bionano Genomics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.